Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Releases New Version of 2-D Gel Analysis Tool

NEW YORK, Feb 1 – Compugen has released a new version of its Z3 high-throughput two dimensional gel electrophoresis analysis system for proteins, the company announced Thursday.

This system, which the company initially introduced in September, automates the process of analyzing 2D gel separations of complex proteins using proprietary algorithms for gel comparison. Using a color overlay technology, it allows comparison of protein expression in normal and diseased tissues.

" In addition to significantly reducing the analysis time, the new version also introduces a unique feature which allows extracting comprehensive and accurate information from repeated experiments," Amit Rubinfeld, Compugen's Z3 Product Manager, said in a statement.

In the new version, users can create one image from several gels of the same sample, a protein annotation feature, and prediction algorithms for the PI and mass of protein components. The new version also supports Windows 2000, Windows 98, and NT 4.0.

The company charges $29,000 per one-year license, but add-on features are extra.

Compugen’s customers for its Z3 system include the Australian Proteome Analysis Facility, Aventis Pharma, Genentech, NV Organon, Pfizer, Procter & Gamble, [email protected], and Proteologics.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.